{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu YL"],"funding":["Medical Scientific Research Foundation of Guangdong Province, China"],"pagination":["e01657"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7375089"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(7)"],"pubmed_abstract":["<h4>Introduction</h4>To assess whether the asymmetrical cortical vessel sign (ACVS) on susceptibility-weighted imaging (SWI) could predict 90-day poor outcomes in anterior circulation acute ischemic stroke (AIS) patients treated with recombinant tissue plasminogen activator (r-tPA).<h4>Methods</h4>Clinical data of consecutive patients with anterior circulation AIS treated with r-tPA were retrospectively analyzed. Clinical variables included age, sex, vascular risk factors, NIHSS score, onset to treatment time, and initial hematologic and neuroimaging findings. Follow-up was performed 90 days after onset. Poor outcome was defined as a modified Rankin scale (mRS) ≥3 at 90 days.<h4>Results</h4>A total of 145 patients were included, 35 (24.1%) patients presented with ACVS (≥Grade 1) on SWI. Fifty-three (36.6%) patients had a poor outcome at 90 days. ACVS (≥Grade 1) occurred in 21 (39.6%) patients with poor outcome compared with 14 (15.2%) patients with favorable outcome (p = .001). Univariate analysis indicated that age, NIHSS score on admission, previous stroke, hemorrhagic transformation, severe intracranial large artery stenosis or occlusion (SILASO), and ACVS were associated with 90-day poor outcome (p < .05). Since SILASO and ACVS were highly correlated and ACVS had different grades, we used three logistic regression models. Results from the three models showed that ACVS was associated with 90-day poor outcome.<h4>Conclusions</h4>In r-tPA-treated patients with anterior circulation AIS, ACVS might be a helpful neuroimaging predictor for poor outcome at 90 days."],"journal":["Brain and behavior"],"pubmed_title":["Asymmetrical cortical vessel sign predicts prognosis after acute ischemic stroke."],"pmcid":["PMC7375089"],"funding_grant_id":["A2018322"],"pubmed_authors":["Lu ZH","Qu JF","Liu YL","Xiao WM","Lu JK","Fang XW","Liang MQ","Wang YZ","Zhong HH","Chen YK"],"additional_accession":[]},"is_claimable":false,"name":"Asymmetrical cortical vessel sign predicts prognosis after acute ischemic stroke.","description":"<h4>Introduction</h4>To assess whether the asymmetrical cortical vessel sign (ACVS) on susceptibility-weighted imaging (SWI) could predict 90-day poor outcomes in anterior circulation acute ischemic stroke (AIS) patients treated with recombinant tissue plasminogen activator (r-tPA).<h4>Methods</h4>Clinical data of consecutive patients with anterior circulation AIS treated with r-tPA were retrospectively analyzed. Clinical variables included age, sex, vascular risk factors, NIHSS score, onset to treatment time, and initial hematologic and neuroimaging findings. Follow-up was performed 90 days after onset. Poor outcome was defined as a modified Rankin scale (mRS) ≥3 at 90 days.<h4>Results</h4>A total of 145 patients were included, 35 (24.1%) patients presented with ACVS (≥Grade 1) on SWI. Fifty-three (36.6%) patients had a poor outcome at 90 days. ACVS (≥Grade 1) occurred in 21 (39.6%) patients with poor outcome compared with 14 (15.2%) patients with favorable outcome (p = .001). Univariate analysis indicated that age, NIHSS score on admission, previous stroke, hemorrhagic transformation, severe intracranial large artery stenosis or occlusion (SILASO), and ACVS were associated with 90-day poor outcome (p < .05). Since SILASO and ACVS were highly correlated and ACVS had different grades, we used three logistic regression models. Results from the three models showed that ACVS was associated with 90-day poor outcome.<h4>Conclusions</h4>In r-tPA-treated patients with anterior circulation AIS, ACVS might be a helpful neuroimaging predictor for poor outcome at 90 days.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2025-04-19T11:40:30.369Z","creation":"2025-04-19T11:40:30.369Z"},"accession":"S-EPMC7375089","cross_references":{"pubmed":["32436291"],"doi":["10.1002/brb3.1657"]}}